Curated News
By: NewsRamp Editorial Staff
March 09, 2026
NRx Opens Florida Clinic with 87% Success Rate for Depression Treatment
TLDR
- NRx Pharmaceuticals expands its HOPE Therapeutics clinic network in Florida, offering advanced depression and PTSD treatments that could capture market share in mental health care.
- HOPE Therapeutics uses ketamine, TMS, hyperbaric oxygen therapy, and psychotherapy in an interventional psychiatry approach, with studies showing 87% response rates in treatment-resistant depression.
- This clinic provides innovative treatments for depression and PTSD, potentially improving patient outcomes and offering new hope for those with treatment-resistant conditions.
- A new Florida clinic combines ketamine, brain stimulation, and oxygen therapy to treat depression, with pilot programs showing 90% return-to-function rates for PTSD patients.
Impact - Why it Matters
This development matters because it addresses a critical gap in mental healthcare, particularly for treatment-resistant conditions like depression and PTSD that affect millions globally. Traditional therapies often fail for these patients, leading to prolonged suffering, disability, and high suicide risks. NRx's interventional approach, backed by compelling data showing high response and return-to-function rates, offers new hope where other options have fallen short. By expanding access through clinics and advancing FDA-designated drugs, it could significantly improve patient outcomes, reduce healthcare burdens, and set a precedent for innovative neuroplastic treatments. For investors, it signals growth in a high-need market, while for the public, it represents a tangible step toward more effective mental health solutions.
Summary
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has announced a significant expansion through its subsidiary HOPE Therapeutics. The company has opened a new interventional psychiatry clinic in Palm Beach, Florida, dedicated to treating severe mental health conditions like depression and post-traumatic stress disorder (PTSD). This facility employs a comprehensive, multi-modal approach that includes ketamine and other neuroplastic drugs, transcranial magnetic stimulation (TMS), hyperbaric oxygen therapy, and physician-led psychotherapy. The move builds on HOPE's growing network and a nationwide partnership with neurocare AG, aiming to bring advanced, non-invasive neuroplastic therapies to more patients. The company cites impressive clinical data, with peer-reviewed publications reporting an 87% clinical response rate in treatment-resistant depression using short-term protocols, and pilot programs showing a 90% return-to-function rate for patients with depression and PTSD when incorporating hyperbaric oxygen therapy.
NRx Pharmaceuticals is developing its therapeutics based on an NMDA platform, targeting central nervous system disorders including suicidal depression, chronic pain, and PTSD. Its key pipeline products are NRX-100, a preservative-free intravenous ketamine with Fast Track Designation for suicidal ideation, and NRX-101, an oral combination therapy with Breakthrough Therapy Designation for suicidal bipolar depression. The company has initiated regulatory filings, including an Abbreviated New Drug Application (ANDA) and a New Drug Application for NRX-100, seeking priority status for treating suicidal ideation. This news was distributed via the BioMedWire platform, part of the InvestorBrandNetwork's Dynamic Brand Portfolio, which provides extensive financial communications services including press release enhancement and syndication to over 5,000 outlets. For more details, investors can visit the company's newsroom or the full press release link.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NRx Opens Florida Clinic with 87% Success Rate for Depression Treatment
